Marek Honczarenko Healthcare News

Follow[dot]Health is a news alert service for Heathcare and Healthtech. We are following 40K entities across 30M news items - with 1M items added monthly. This is selected healthcare news for Marek Honczarenko, which is filed under People. There are 8 news items for this page.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source
5/27/2020 AbbVie Presents New Data at the European E-Congress of Rheumatology (EULAR) 2020 Showcasing Depth of its Rheumatology Portfolio
... rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. "As a leader in immunology for over two decades, AbbVie is dedicated to developing innovative therapies for patients living with debilitating, chronic immune-mediated conditions," said Marek Honczarenko MD, PhD, vice president, global immunology development, AbbVie. "The new research from across our portfolio ...
PR Newswire
11/12/2019 New Positive Data for RINVOQ™ (upadacitinib) on Signs and Symptoms in Patients with Ankylosing Spondylitis Presented at 2019 ACR/ARP Annual Meeting
... for patients living with ankylosing spondylitis." "Results from the SELECT-AXIS 1 study show that RINVOQ was able to provide significant improvements to signs and symptoms for patients living with ankylosing spondylitis," said Marek Honczarenko, M.D., Ph.D., vice president, immunology development, AbbVie. "These data highlight AbbVie's commitment to discovering and ...
PR Newswire
11/4/2019 AbbVie to Showcase Depth of Immunology Portfolio and Pipeline at the 2019 ACR/ARP Annual Meeting
... psoriatic arthritis (PsA). "AbbVie looks forward to sharing the latest research across our recently expanded rheumatology portfolio at this year's meeting, including data that further support our recent FDA approval of RINVOQ," said Marek Honczarenko , M.D., Ph.D., vice president, global immunology development, AbbVie. "New data being presented on upadacitinib, risankizumab ...
PR Newswire
11/4/2019 AbbVie to Showcase Depth of Immunology Portfolio and Pipeline at the 2019 ACR/ARP Annual Meeting BioSpace
11/4/2019 AbbVie to Showcase Depth of Immunology Portfolio and Pipeline at the 2019 ACR/ARP Annual Meeting tncontentexchange.com
10/9/2019 AbbVie Announces New Data from its Dermatology Portfolio and Pipeline at the 28th European Academy of Dermatology and Venereology (EADV) Congress PR Newswire
6/11/2019 New Two-Year Data at the 24th World Congress of Dermatology Shows SKYRIZI™ (risankizumab) Maintains Complete Skin Clearance PR Newswire